Table 2.
Enriched CNS Gene Sets, Combined Analysis
Ngene | Combined |
Deletion |
Duplication |
|||||
---|---|---|---|---|---|---|---|---|
p | Padj | OR (95% CI) | p | Padj | p | Padj | ||
NMDAR network | 59 | 4.3×10−9 | 1.7×10−6 | 2.47 (1.8–3.44) | 0.045 | 1 | 2.5×10−9 | 1.0×10−6 |
GABAA | 15 | 3.0×10−6 | 0.0012 | 2.51 (1.65–3.97) | 0.00068 | 0.27 | 5.4×10−5 | 0.022 |
Abnormal associative learning | 193 | 1.6×10−5 | 0.0066 | 1.38 (1.19–1.61) | 1.0 | 1 | 1.6×10−10 | 6.2×10−8 |
Abnormal long-term potentiation | 145 | 2.0×10−5 | 0.0081 | 1.49 (1.24–1.8) | 0.58 | 1 | 1.1×10−6 | 0.00044 |
Abnormal behavior | 1,973 | 5.1×10−5 | 0.020 | 1.12 (1.06–1.19) | 3.0×10−6 | 0.0012 | 0.05 | 1 |
Abnormal CNS synaptic transmission | 371 | 5.5×10−5 | 0.022 | 1.22 (1.11–1.35) | 5.1×10−6 | 0.002 | 0.12 | 1 |
Thin cerebral cortex | 45 | 0.00018 | 0.071 | 1.91 (1.32–2.8) | 0.12 | 1 | 0.0006 | 0.24 |
Abnormal consumption behavior | 442 | 0.00019 | 0.077 | 1.24 (1.09–1.41) | 0.059 | 1 | 0.0005 | 0.2 |
Abnormal cued conditioning behavior | 68 | 0.00027 | 0.11 | 1.69 (1.24–2.35) | 0.55 | 1 | 1.4×10−5 | 0.0055 |
Abnormal synaptic transmission | 437 | 0.00027 | 0.11 | 1.18 (1.08–1.29) | 1.1×10−5 | 0.0044 | 0.21 | 1 |
Abnormal learning/memory/conditioning | 424 | 0.00031 | 0.12 | 1.18 (1.08–1.29) | 7.3×10−5 | 0.029 | 0.089 | 1 |
PSD-95 (core) | 58 | 0.00048 | 0.19 | 1.71 (1.28–2.28) | 4.3×10−11 | 1.7×10−8 | 0.97 | 1 |
Abnormal contextual conditioning behavior | 89 | 0.00061 | 0.24 | 1.53 (1.18–1.99) | 0.52 | 1 | 0.00011 | 0.045 |
CNS gene sets with Puncorrected < 0.001 in the combined analysis of deletions and duplications are listed along with the number of genes in each set, Ngene; uncorrected (p) and Bonferroni-corrected (Padj) p values for enrichment in case CNVs; estimated odds ratios (OR); and p values for enrichment in case deletions and duplications when analyzed separately. Note that while the NMDAR network was analyzed prior to other terms in this table, here it is corrected for the same number of tests as other terms for ease of comparison. See also Tables S1 and S3.